
    
      A randomised placebo controlled double blind multi-centre phase II trial: BIBF 1120 200mg bd
      plus 100mg daily of oral cyclophosphamide (experimental arm) or oral cyclophosphamide 100mg
      daily plus placebo (control arm). Patients will receive oral BIBF 1120 and cyclophosphamide
      or cyclophosphamide and placebo continuously until disease progression or unacceptable
      toxicity.
    
  